Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pain, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02719015 2017-11-24

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT02736123 2017-09-20

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT01833767 2017-08-24

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT02210104 2017-07-21

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Phase 1 Withdrawn

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT01843738 2017-05-24

Radiation Use During Vemurafenib Treatment

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT02400385 2017-02-01

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Phase 3 Withdrawn

Dermatologic

Melanoma

NCT01312506 2016-07-27

Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls

Withdrawn

Dermatologic

Melanoma, Neoplasm Metastasis

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Skin Neoplasms

NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02452281 2016-01-25

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT02357732 2015-12-11

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT00006126 2015-11-13

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Phase 1 Withdrawn

BreastDermatologicGenitourinaryThoracic

Testicular Germ Cell Tumor, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Testicular Neoplasms, Small Cell Lung Carcinoma

NCT02507076 2015-07-23

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Phase NA Withdrawn

DermatologicSarcoma

Carcinoma, Basal Cell, Melanoma, Sarcoma, Skin Neoplasms

Clinical Trials

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Sargramostim (GM-CSF) + PD-1

SERPENTINE

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

SBRT as a Vaccination for Metastatic Melanoma

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

PPD1

Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

UVA-AM-002

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

A Clinical Trial of Patients With Melanoma

REO13 Melanoma With of Without GM-CSF

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Radiation Use During Vemurafenib Treatment

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma